Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LRMR
LRMR | US
4.38
USD-0.02
-0.45%
LRMR | US
Loading StockChartView...
About LRMR
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/03/2026
Close
4.38
Open
4.40
High
4.50
Low
4.30
Larimar Therapeutics Inc. a clinical-stage biotechnology company focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601 which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia a rare progressive and fatal genetic disease. The company is headquartered in Bala Cynwyd Pennsylvania.
View LessLRMR | US
Risk
253.1
Sharpe
0.53
Luna's Score
52/100
Recommendation
Hold
Luna says (LRMR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
86.1%1 month
253.1%3 months
155.7%6 months
139.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.33
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-4.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-65.51M
MarketCap
279.47M
MarketCap(USD)
279.47M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-37.48
Short ratio
4.63
Short perc.
8.57
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.70
Range1M
3.71
Range3M
3.71
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.15
Price X volume
6.23M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.13 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.33 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 155.66 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 279.47M | 3.66B | Emerging |
